Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases

Detalhes bibliográficos
Autor(a) principal: Jordy,Sergio Semeraro
Data de Publicação: 2008
Outros Autores: Tilbery,Charles Peter, Fazzito,Mirella Martins
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2008000100004
Resumo: BACKGROUND: Since 1997, immunological modulators have been used for treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in the Multiple Sclerosis Attendance and Treatment Center (CATEM) with significant alterations in this disease natural history. AIM: To add data on the experience of CATEM for the treatment of RRMS patients that had immunomodulators. METHOD: RRMS patients that received continuously immunomodulator drugs were evaluated on adherence, migration, withdrawal and progression rates. The patients were divided in three groups by the period of immunomodulators intake. RESULTS: There were registered in Group 1 withdrawal in 98 patients (25%) and adherence in 292 cases (74%); Group 2 interruption of therapy in 140 patients, 92 (31%) due to progression for PSMS, 14 (5%) for pregnancy, withdrawal in 34 (11%), adherence in 88%; Group 3 progression in 41 (26%), pregnancy in 3 (2%) withdrawal in 42 (27%) and adherence in 72%. The migration rate was about one third (31.57%) and the principal cause was therapeutic failure; the mean migrating time was 0.5-2.5 years in group 3. CONCLUSION: Immunomodulatory treatment for RRMS patients may have significant levels of failure and side effects; the adherence was compatible with the international literature.
id ABNEURO-1_cc1ae1098466f99371389affd6c777b7
oai_identifier_str oai:scielo:S0004-282X2008000100004
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 casesmultiple sclerosistreatmentimmunomodulatorsadherencemigrationwithdrawalBACKGROUND: Since 1997, immunological modulators have been used for treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in the Multiple Sclerosis Attendance and Treatment Center (CATEM) with significant alterations in this disease natural history. AIM: To add data on the experience of CATEM for the treatment of RRMS patients that had immunomodulators. METHOD: RRMS patients that received continuously immunomodulator drugs were evaluated on adherence, migration, withdrawal and progression rates. The patients were divided in three groups by the period of immunomodulators intake. RESULTS: There were registered in Group 1 withdrawal in 98 patients (25%) and adherence in 292 cases (74%); Group 2 interruption of therapy in 140 patients, 92 (31%) due to progression for PSMS, 14 (5%) for pregnancy, withdrawal in 34 (11%), adherence in 88%; Group 3 progression in 41 (26%), pregnancy in 3 (2%) withdrawal in 42 (27%) and adherence in 72%. The migration rate was about one third (31.57%) and the principal cause was therapeutic failure; the mean migrating time was 0.5-2.5 years in group 3. CONCLUSION: Immunomodulatory treatment for RRMS patients may have significant levels of failure and side effects; the adherence was compatible with the international literature.Academia Brasileira de Neurologia - ABNEURO2008-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2008000100004Arquivos de Neuro-Psiquiatria v.66 n.1 2008reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/S0004-282X2008000100004info:eu-repo/semantics/openAccessJordy,Sergio SemeraroTilbery,Charles PeterFazzito,Mirella Martinseng2008-03-28T00:00:00Zoai:scielo:S0004-282X2008000100004Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2008-03-28T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases
title Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases
spellingShingle Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases
Jordy,Sergio Semeraro
multiple sclerosis
treatment
immunomodulators
adherence
migration
withdrawal
title_short Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases
title_full Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases
title_fullStr Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases
title_full_unstemmed Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases
title_sort Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases
author Jordy,Sergio Semeraro
author_facet Jordy,Sergio Semeraro
Tilbery,Charles Peter
Fazzito,Mirella Martins
author_role author
author2 Tilbery,Charles Peter
Fazzito,Mirella Martins
author2_role author
author
dc.contributor.author.fl_str_mv Jordy,Sergio Semeraro
Tilbery,Charles Peter
Fazzito,Mirella Martins
dc.subject.por.fl_str_mv multiple sclerosis
treatment
immunomodulators
adherence
migration
withdrawal
topic multiple sclerosis
treatment
immunomodulators
adherence
migration
withdrawal
description BACKGROUND: Since 1997, immunological modulators have been used for treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in the Multiple Sclerosis Attendance and Treatment Center (CATEM) with significant alterations in this disease natural history. AIM: To add data on the experience of CATEM for the treatment of RRMS patients that had immunomodulators. METHOD: RRMS patients that received continuously immunomodulator drugs were evaluated on adherence, migration, withdrawal and progression rates. The patients were divided in three groups by the period of immunomodulators intake. RESULTS: There were registered in Group 1 withdrawal in 98 patients (25%) and adherence in 292 cases (74%); Group 2 interruption of therapy in 140 patients, 92 (31%) due to progression for PSMS, 14 (5%) for pregnancy, withdrawal in 34 (11%), adherence in 88%; Group 3 progression in 41 (26%), pregnancy in 3 (2%) withdrawal in 42 (27%) and adherence in 72%. The migration rate was about one third (31.57%) and the principal cause was therapeutic failure; the mean migrating time was 0.5-2.5 years in group 3. CONCLUSION: Immunomodulatory treatment for RRMS patients may have significant levels of failure and side effects; the adherence was compatible with the international literature.
publishDate 2008
dc.date.none.fl_str_mv 2008-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2008000100004
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2008000100004
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-282X2008000100004
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.66 n.1 2008
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212763296595968